title: Thyroid hormone replacement for subclinical hypothyroidism.
abstract: BACKGROUND
  Subclinical hypothyroidism is defined as an elevated serum thyroid-stimulating hormone (TSH) level with normal free thyroid hormones values. The prevalence of subclinical hypothyroidism is 4% to 8% in the general population, and up to 15% to 18% in women who are over 60 years of age. There is considerable controversy regarding the morbidity, the clinical significance of subclinical hypothyroidism and if these patients should be treated.
  
  
  OBJECTIVE
  To assess the effects of thyroid hormone replacement for subclinical hypothyroidism.
  
  
  METHODS
  We searched The Cochrane Library, MEDLINE, EMBASE and LILACS. Ongoing trials databases, reference lists and abstracts of congresses were scrutinized as well.
  
  
  METHODS
  All studies had to be randomised controlled trials comparing thyroid hormone replacement with placebo or no treatment in adults with subclinical hypothyroidism. Minimum duration of follow-up was one month.
  
  
  METHODS
  Two authors independently assessed trial quality and extracted data. We contacted study authors for missing or additional information.
  
  
  RESULTS
  Twelve trials of six to 14 months duration involving 350 people were included. Eleven trials investigated levothyroxine replacement with placebo, one study compared levothyroxine replacement with no treatment. We did not identify any trial that assessed (cardiovascular) mortality or morbidity. Seven studies evaluated symptoms, mood and quality of life with no statistically significant improvement. One study showed a statistically significant improvement in cognitive function. Six studies assessed serum lipids, there was a trend for reduction in some parameters following levothyroxine replacement. Some echocardiographic parameters improved after levothyroxine replacement therapy, like myocardial relaxation, as indicated by a significant prolongation of the isovolumic relaxation time as well as diastolic dysfunction. Only four studies reported adverse events with no statistically significant differences between groups.
  
  
  CONCLUSIONS
  In current RCTs, levothyroxine replacement therapy for subclinical hypothyroidism did not result in improved survival or decreased cardiovascular morbidity. Data on health-related quality of life and symptoms did not demonstrate significant differences between intervention groups. Some evidence indicates that levothyroxine replacement improves some parameters of lipid profiles and left ventricular function.
authors.affiliation: Faculdade Estadual de Medicina de Marília, Departamento de Medicina Interna, Av. Cascata 123, Marília, São Paulo, Brazil, 17515-300. hvillar@famema.br
authors.forename: H C C E
authors.initials: HC
authors.lastname: Villar
authors.forename: H
authors.initials: H
authors.lastname: Saconato
authors.forename: O
authors.initials: O
authors.lastname: Valente
authors.forename: A N
authors.initials: AN
authors.lastname: Atallah
mesh_terms: D000328:Adult; D002319:Cardiovascular System / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D007037:Hypothyroidism / Q000097:blood / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013974:Thyroxine / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D002784:Cholesterol; D013974:Thyroxine